Sign In
SPPI.US
id: 1592

Spectrum Pharmaceuticals (SPPI) $15.95M Investor Settlement

The court has approved the settlement.
$15,950,000
Cash Settlement
D. Nevada
Court
2:21-cv-01612
Case number
03/07/2018
Class period Start
08/05/2021
Class period End

Spectrum Pharmaceuticals ($SPPI) has agreed to settle $15.95 million with investors to resolve claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates.

Case Type
US Securities Class Action
Case Status
Preliminary Approved Settlement
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.06
Filing date
08/31/2021
Plaintiffs
International Trading Group
Attorneys
Robbins Geller Rudman & Dowd LLP
Defendants
Joseph W. Turgeon ; Kurt A. Gustafson; Francois J. Lebel, M.D. ; Thomas J. Riga
Judge
Cristina D. Silva
Administrator
Verita Global
Attorney fee
$4,985,000
Trades matching type
FIFO

Frequently Asked Questions

Who is eligible for this settlement?
Do I have to sell securities to be eligible?
How long does the payout process take?
How much will my payment be?
How to get your payout?
What is 11th.com?

Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulatin...

    Ticker
    SPPI.US
    ISIN
    US84763A1088
    CIK
    0000831547
    Sector
    Healthcare
    Industry
    Biotechnology & Medical Research
    Country
    USA
    Address
    Pilot House ? Lewis Wharf, Boston, MA, United States, 02110